Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Current Deferred Revenue (2020 - 2022)

Neuroone Medical Technologies (NMTC) has disclosed Current Deferred Revenue for 3 consecutive years, with $1.5 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Current Deferred Revenue rose 16777.62% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Sep 2022, up 16777.62%, and an annual FY2022 reading of $1.5 million, up 16777.62% over the prior year.
  • Current Deferred Revenue was $1.5 million for Q3 2022 at Neuroone Medical Technologies, up from $2248.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.5 million in Q3 2022 and bottomed at $2248.0 in Q4 2021.
  • Average Current Deferred Revenue over 3 years is $195794.6, with a median of $11109.0 recorded in 2021.
  • The sharpest move saw Current Deferred Revenue crashed 95.61% in 2021, then surged 16777.62% in 2022.
  • Year by year, Current Deferred Revenue stood at $51160.0 in 2020, then plummeted by 95.61% to $2248.0 in 2021, then skyrocketed by 64632.56% to $1.5 million in 2022.
  • Business Quant data shows Current Deferred Revenue for NMTC at $1.5 million in Q3 2022, $2248.0 in Q2 2022, and $2248.0 in Q1 2022.